Bronchogen
AEDL peptide, Ala-Glu-Asp-Leu, Chonluten (related bronchial preparation)
Bronchogen is a four-amino-acid Khavinson peptide directed at bronchial epithelium and promoted for respiratory function. Its published record runs to roughly twelve PubMed-indexed papers, all preclinical and almost all from the originating Russian network, covering DNA binding and thermostability, gene expression in plants and a rat model of obstructive lung pathology. No human trial exists.
Mechanism
Bronchogen is assigned within the Khavinson framework to bronchial epithelial tissue. The proposed mechanism is the same as for the rest of the series: nuclear entry and direct interaction with promoter DNA, altering transcription. For AEDL specifically there is a slightly more concrete physical observation than for most of the series. A differential scanning calorimetry study reported that Bronchogen alters the thermal stability of DNA, consistent with the peptide binding the double helix and changing its melting behaviour, and a separate fluorescence-quenching study reported that AEDL binds preferentially to oligonucleotides containing CNG and specifically CTG sequences.
A second and unusual line of evidence comes from plant biology: short exogenous peptides including AEDL were reported to regulate expression of CLE, KNOX1 and GRF family genes in tobacco. This is genuinely interesting as evidence that these peptides can influence transcription across kingdoms, but it cuts both ways. A peptide that alters gene expression in tobacco, mouse and human cells alike is unlikely to be exerting the tissue-specific, organ-matched regulation that the marketing model requires. Generic nucleic acid interaction and organ-selective gene targeting are competing explanations, and the plant data favours the former.
The reported biological effect in respiratory tissue is modulation of bronchial epithelial morphology and function, with claimed reduction of the epithelial remodelling that occurs in chronic obstructive lung disease.
What the research shows
The strongest study is a 2015 rat experiment in Bulletin of Experimental Biology and Medicine. Chronic obstructive pulmonary disease was modelled by 60 days of intermittent nitrogen dioxide exposure, after which one month of Bronchogen was reported to eliminate the characteristic remodelling features, goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema, with restoration of ciliated cells, increased secretory IgA and normalisation of the cell composition and proinflammatory cytokine profile of the bronchoalveolar space. That is a broad claim from a single small animal study in one laboratory, and it has not been replicated. A 2011 calorimetry study reported that Bronchogen changes DNA thermostability. A 2011 fluorescence study found AEDL binding preferentially to CTG-containing oligonucleotides. A 2017 study in Biochemistry (Moscow) reported regulation of developmental gene families in tobacco.
There is no human study of Bronchogen of any description. No registered clinical trial, no pharmacokinetics, no toxicology, no dose-finding. The related preparation Chonluten (Glu-Asp-Gly), a tripeptide from the same programme also assigned to bronchial epithelium, has its own separate and very small literature, but that concerns a different molecule.
For a compound sold to people with asthma or chronic obstructive pulmonary disease, the absence of human data is the material fact. Chronic obstructive pulmonary disease has well-characterised treatments with demonstrated effects on exacerbation rate and mortality; substituting an unevidenced peptide is a decision with real downside.
Evidence assessment
Preclinical only
About twelve indexed papers, all cell culture, biophysical, plant or rodent work from the originating network, with no human trial, no pharmacokinetics and no toxicology.
Tiers are applied consistently across the library and re-checked when new trials read out. Read the grading method.
Key studies
Modulating Effect of Peptide Therapy on the Morphofunctional State of Bronchial Epithelium in Rats with Obstructive Lung Pathology Preclinical only
Reported elimination of goblet cell hyperplasia, squamous metaplasia, lymphocytic infiltration and emphysema with restoration of ciliated cells, increased secretory IgA and normalisation of bronchoalveolar cell composition and cytokine profile.
Effect of the peptide bronchogen (Ala-Asp-Glu-Leu) on DNA thermostability Preclinical only
Bronchogen altered the thermal melting profile of DNA, consistent with direct binding to the double helix.
Penetration of short fluorescence-labeled peptides into the nucleus in HeLa cells and in vitro specific interaction of the peptides with deoxyribooligonucleotides and DNA Preclinical only
Bronchogen, given here as Ala-Glu-Asp-Leu, bound preferentially to oligonucleotides containing CNG and specifically CTG sequences, distinguishing it from epithalon and pinealon which preferred CAG.
Short Exogenous Peptides Regulate Expression of CLE, KNOX1, and GRF Family Genes in Nicotiana tabacum Preclinical only
Short peptides including AEDL altered expression of developmental gene families in tobacco.
Peptides tissue-specifically stimulate cell differentiation during their aging Preclinical only
Reported tissue-preferential stimulation of differentiation by short peptides including AEDL.
Safety
No formal safety characterisation in humans or animals. No toxicology, no adverse event record, no dose-ranging. Material sold online is unregulated and its identity, purity and sterility are unverified, a problem compounded by the residue-order inconsistency in the source literature. Because Bronchogen is marketed for respiratory conditions, the practical risk is displacement of inhaled therapies with established benefit.
Regulatory status
| Jurisdiction | Status |
|---|---|
| United Kingdom | No MHRA marketing authorisation. Supply for human use engages the Human Medicines Regulations 2012 regardless of a 'research use only' label. |
| United States | Not approved by the FDA, never studied under an investigational new drug application, absent from clinical trial registries. Sold as a research chemical. |
| WADA (sport) | Not individually named on the Prohibited List but captured by section S0 (non-approved substances), prohibited at all times. |
Questions
No. There is no registered clinical trial and no published human study of any kind. The respiratory evidence consists of a single rat model in which COPD was induced by 60 days of nitrogen dioxide exposure.
That Bronchogen changes the temperature at which DNA melts, which is consistent with the peptide binding the double helix. It does not show that this binding occurs at physiological concentrations or produces any biological effect in a living organism.
Because it suggests the peptide interacts with nucleic acids generically rather than selecting human bronchial promoters. Cross-kingdom activity is hard to reconcile with the claim that each Khavinson peptide is matched to one organ in one species.
No. Chonluten is the tripeptide Glu-Asp-Gly from the same programme, also assigned to bronchial epithelium. They are different molecules and the small literatures on each should not be pooled.